Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,598,095
  • Shares Outstanding, K 68,120
  • Annual Sales, $ 753,800 K
  • Annual Income, $ 125,300 K
  • 36-Month Beta 0.32
  • Price/Sales 2.16
  • Price/Cash Flow N/A
  • Price/Book 2.16

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.34 +0.51%
on 07/27/17
26.37 -11.04%
on 06/28/17
-1.95 (-7.67%)
since 06/27/17
3-Month
18.09 +29.68%
on 04/28/17
26.99 -13.08%
on 06/22/17
+5.13 (+27.99%)
since 04/27/17
52-Week
15.15 +54.85%
on 02/07/17
32.54 -27.90%
on 07/28/16
-9.03 (-27.79%)
since 07/27/16

Most Recent Stories

More News
Top 10 Companies in Liquid Biopsy Detailed in New Report

New York City-based healthcare market researcher Kalorama Information details the top 10 liquid biopsy companies and their activities in a new report. The market, Kalorama says, is heterogeneous and very...

MYGN : 23.46 (-1.18%)
Myriad Genetics to Grow with Study Successes, New Alliances

On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).

MLAB : 143.49 (-1.08%)
MYGN : 23.46 (-1.18%)
ALGN : 157.26 (-0.90%)
INGN : 94.27 (-1.48%)
Global Market for Laboratory-Developed Testing - Expected to Increase from Nearly $11 Billion in 2016 to $14.9 Billion in 2021

Research and Markets has announced the addition of the "Laboratory-developed Testing: Technologies and Markets" report to their offering. The report includes an overview of the global market for laboratory-developed...

ENZ : 10.97 (-2.83%)
MKGAY : 38.3600 (-0.62%)
GHDX : 32.05 (-2.88%)
DGX : 108.99 (+0.71%)
MYGN : 23.46 (-1.18%)
Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%

Myriad Genetics, Inc. (MYGN) moved big last session, as its shares rose over 5% on the day.

VVUS : 1.14 (-3.78%)
MYGN : 23.46 (-1.18%)
Virginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Virginia ("Gina") C. Drosos, president of Assurex Health, a wholly-owned subsidiary...

MYGN : 23.46 (-1.18%)
Crescendo Bioscience Announces Six Studies with Vectra(R) DA Will Be Presented at the 2017 Annual European Congress of Rheumatology

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra DA test will be presented at the European League Against Rheumatism...

MYGN : 23.46 (-1.18%)
Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive

Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.

AXDX : 27.10 (-2.17%)
MYGN : 23.46 (-1.18%)
ALGN : 157.26 (-0.90%)
INGN : 94.27 (-1.48%)
Why Is Myriad Genetics (MYGN) Down 9.6% Since the Last Earnings Report?

Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MYGN : 23.46 (-1.18%)
Myriad's BRACAnalysis CDx(R) Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDxcompanion diagnostic test successfully identified BRCA-mutated...

MYGN : 23.46 (-1.18%)
Myriad Announces 17 Additional Health Insurance Plans Covering EndoPredict(TM)

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict....

MYGN : 23.46 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease....

See More

Support & Resistance

2nd Resistance Point 24.23
1st Resistance Point 23.85
Last Price 23.46
1st Support Level 23.21
2nd Support Level 22.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.